Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 13

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 13
---
 summary of provisions contained in Section 13.9 of the Articles, is in addition to any other requirements under applicable laws, is not comprehensive and is qualified by the full text of such provisions. The full text of such provisions is set out in Section 13.9 of the Articles, as amended, copies of which are filed as Exhibits 3.1 and 3.2 to our Annual Report on Form 10-K for the year ended December 31, 2024, which can be found under our profile at www.sedarplus.ca or www.sec.gov. In addition to satisfying the foregoing advance notice requirements under our Articles, to comply with the universal proxy rules under the Exchange Act, Shareholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide written notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March 23, 2026, which is the first business day following the 60 thday prior to the one-year anniversary date of the Annual Meeting. It is recommended that Shareholders submitting proposals utilize certified mail with return receipt requested to provide proof of timely receipt. The Chair of the Annual Meeting reserves the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with these and other applicable requirements, including conditions set forth in our Articles and conditions established by the SEC. 5 TABLE OF CONTENTS Whom should I contact if I have questions concerning the Proxy Statement/Circular or voting? If you have questions concerning the information contained in this Proxy Statement/Circular, you may contact us by letter, phone or through our website as follows: Arbutus Biopharma Corporation Attn: Gloria Pichii 701 Veterans Circle Warminster, Pennsylvania 18974, United States Phone: 267.469.0914 Website: http://www.arbutusbio.com/ 6 TABLE OF CONTENTS PROPOSALS PROPOSAL NO. 1 – ELECTION OF DIRECTORS Our Board currently consists of five (5) directors. The term of office of each of the current directors will end immediately before the election of directors at the Annual Meeting. Unless the director’s office is earlier vacated in accordance with the provisions of the BCBCA and our Articles, each director elected will hold office until immediately before the election of new directors at the next annual general meeting of our Shareholders and, if no director is then elected, until a qualified successor is duly elected or appointed